news
P&G pays up for Thorne, signaling supplement industry's future
Procter & Gamble just dropped a hefty sum for Thorne, the supplement manufacturer known for its science-backed formulas. Industry watchers see this as a big vote of confidence for supplements and personalized health, suggesting where the market's headed next.
Procter & Gamble just dropped a hefty sum for Thorne, the supplement manufacturer known for its science-backed formulas. Industry watchers see this as a big vote of confidence for supplements and personalized health, suggesting where the market's headed next.
The architecture take
P&G buying Thorne isn't just a big-brand flex; it's a bet on the consumer who wants data to back up their pill popping. Thorne's whole pitch is 'testing, then supplementing,' targeting specific mechanisms like gut health, mitochondrial function, or hormone balance. This isn't your grandma's generic multivitamin brand. What P&G is really buying is a slice of the 'self-quantification' pie, where people track everything from HRV to blood sugar, then expect precise recommendations. It means the big players are finally paying attention to the fact that 'wellness' is getting less woo-woo and more clinical. Watch for more major CPGs to acquire smaller, science-led brands that speak to specific body systems. Because in the end, if you can actually measure the impact, it sells better than a feeling.